CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.335 EUR | +6.35% |
|
-1.33% | -14.10% |
| 04/04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 09/02 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 198.1 | 135.2 | 92.3 | 79.42 | 11.43 | 16.16 |
| Enterprise Value (EV) 1 | 150 | 100.3 | 78.7 | 52.03 | -0.7575 | 10.21 |
| P/E ratio | -4.94 x | -4.24 x | -5.36 x | -2.07 x | -0.28 x | -1.19 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 63.6 x | 22,540 x | 18,460 x | - | - | 158 x |
| EV / Revenue | 48.2 x | 16,711 x | 15,740 x | - | - | 100 x |
| EV / EBITDA | -4.79 x | -3.48 x | -3.07 x | -1.95 x | 0.04 x | -1.13 x |
| EV / FCF | -9.85 x | -6.88 x | -7.09 x | -3.86 x | 0.07 x | -0.71 x |
| FCF Yield | -10.1% | -14.5% | -14.1% | -25.9% | 1,398% | -142% |
| Price to Book | 3.56 x | 2.96 x | 2.98 x | 1.82 x | 2.65 x | 2.56 x |
| Nbr of stocks (in thousands) | 11,942 | 13,942 | 13,942 | 22,594 | 22,594 | 41,429 |
| Reference price 2 | 16.59 | 9.700 | 6.620 | 3.515 | 0.5060 | 0.3900 |
| Announcement Date | 05/04/19 | 25/03/20 | 24/03/21 | 24/03/22 | 23/03/23 | 04/04/24 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3.115 | 0.006 | 0.005 | - | - | 0.102 |
| EBITDA 1 | -31.34 | -28.83 | -25.6 | -26.68 | -19.55 | -9.004 |
| EBIT 1 | -32.38 | -29.49 | -26.24 | -27.24 | -20.26 | -9.512 |
| Operating Margin | -1,039.61% | -4,91,566.67% | -5,24,800% | - | - | -9,325.49% |
| Earnings before Tax (EBT) 1 | -37.43 | -28.64 | -17.2 | -26.5 | -40.87 | -8.511 |
| Net income 1 | -37.43 | -28.63 | -17.2 | -26.51 | -40.94 | -8.448 |
| Net margin | -1,201.51% | -4,77,200% | -3,44,080% | - | - | -8,282.35% |
| EPS 2 | -3.359 | -2.286 | -1.234 | -1.699 | -1.812 | -0.3284 |
| Free Cash Flow 1 | -15.23 | -14.57 | -11.11 | -13.48 | -10.59 | -14.45 |
| FCF margin | -488.82% | -2,42,852.08% | -2,22,112.5% | - | - | -14,167.89% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 05/04/19 | 25/03/20 | 24/03/21 | 24/03/22 | 23/03/23 | 04/04/24 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 48.1 | 35 | 13.6 | 27.4 | 12.2 | 5.95 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -15.2 | -14.6 | -11.1 | -13.5 | -10.6 | -14.5 |
| ROE (net income / shareholders' equity) | -72.6% | -56.6% | -44.9% | -71% | -171% | -159% |
| ROA (Net income/ Total Assets) | -23.5% | -20% | -21% | -23.3% | -25.4% | -33% |
| Assets 1 | 159 | 143 | 81.78 | 113.7 | 161.1 | 25.58 |
| Book Value Per Share 2 | 4.650 | 3.270 | 2.220 | 1.930 | 0.1900 | 0.1500 |
| Cash Flow per Share 2 | 3.390 | 2.820 | 1.240 | 1.330 | 0.5500 | 0.1700 |
| Capex 1 | 0.83 | 0.42 | 0.15 | 0.33 | 0.12 | 0.9 |
| Capex / Sales | 26.74% | 6,950% | 3,000% | - | - | 881.37% |
| Announcement Date | 05/04/19 | 25/03/20 | 24/03/21 | 24/03/22 | 23/03/23 | 04/04/24 |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.10% | 14.82M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CYAD Stock
- Financials Celyad Oncology SA
